Eyelid Melanoma
What Eyelid Melanoma Is
Eyelid melanoma is a cancer that starts in the pigment-producing cells of the eyelid skin. These cells, called melanocytes, give skin its color. When their DNA gets damaged enough, they can grow out of control and form a tumor. Eyelid melanoma makes up about 1% of all melanomas, which puts it in the rare category.
The lower eyelid is the most common site because it sees the most sun. The most frequent type is lentigo maligna melanoma, followed by superficial spreading melanoma. Both start flat on the skin and can later grow downward into deeper tissue.
Melanoma has a higher chance of spreading than other skin cancers, including basal cell and squamous cell carcinoma. Early thin melanomas have excellent cure rates. Melanoma that has grown deep into the skin or spread to lymph nodes is far more dangerous. Breslow thickness, a measurement of how deep the tumor has grown in millimeters, is the single most important predictor of outcome, per peer-reviewed melanoma guidelines.
A melanoma caught when it is thin and local is a very different disease than one caught after it has spread. Treatment, prognosis, and survival differ dramatically. This is why patient awareness, regular skin checks, and prompt biopsy of suspicious pigmented lesions matter so much.
Warning Signs to Watch For
Dermatologists teach the ABCD rule (sometimes ABCDE) to separate harmless moles from suspicious ones:
- Asymmetry: one half looks different from the other
- Border: edges are irregular, notched, or blurred
- Color: multiple shades, or new color in a previously uniform mole
- Diameter: larger than 6 millimeters (about the size of a pencil eraser)
- Evolution: any change in size, shape, color, or surface
Some features matter especially on the eyelid:
- A new pigmented spot on previously normal skin
- A long-standing mole that starts to grow or change color
- Loss of lashes where the lesion sits
- Bleeding without cause
- A spot that does not match your other moles
Some eyelid melanomas look less like a classic mole. Amelanotic melanoma lacks pigment and can look pink, red, or skin-colored, which can mislead both patients and doctors. A pearly bump that turns out to be melanoma rather than basal cell carcinoma is rare but possible. This is one reason any persistent, changing, or unusual eyelid lesion should be biopsied.
Diagnosis and Staging
Your eye doctor examines the lesion under a slit lamp or dermatoscope. They note size, shape, color variation, border regularity, and whether lashes or the lid margin are affected. They examine the other eyelids, the face, and lymph nodes in front of the ear and along the jaw.
Definitive diagnosis requires a full-thickness skin biopsy. Excisional biopsy (removing the entire lesion) is preferred when feasible because it gives the pathologist a complete view. Incisional biopsy (taking a piece) is used for large lesions where complete removal would be disfiguring before staging is known. Shave biopsy is avoided for suspected melanoma because it can truncate the deepest part of the tumor and obscure the critical Breslow thickness.
Once melanoma is confirmed, staging determines treatment:
- Stage 0 (in situ): melanoma cells confined to the top layer
- Stage I and II: invasive melanoma without lymph node spread
- Stage III: melanoma in regional lymph nodes
- Stage IV: melanoma that has spread to distant organs
Staging uses the AJCC TNM system. Imaging with CT or PET-CT is ordered when needed to check for distant spread.
For melanomas of intermediate thickness (typically Breslow thickness of 0.8 millimeters or greater), sentinel lymph node biopsy may be recommended. A small amount of tracer is injected at the tumor site, and the first (sentinel) lymph node that drains the area is removed and examined under the microscope. This helps detect microscopic spread and guides further treatment.
Treatment Based on Stage
For melanoma in situ, Mohs micrographic surgery is increasingly preferred for periocular lesions. Mohs allows layer-by-layer excision with real-time pathology, preserving tissue on the delicate eyelid. Recurrence rates with Mohs are reported at 0% to 3.6%, compared with 6% to 20% for conventional wide excision, per PMC/NIH 2022 data.
Invasive melanoma is treated with wide local excision. NCCN guidelines recommend margins up to 10 millimeters for thicker melanomas. On the eyelid, achieving these margins without sacrificing vital structures can be difficult, so the procedure is carefully planned by an oculoplastic surgeon working with dermatology and, in some cases, head-and-neck surgery. Reconstruction follows the same principles as for other eyelid cancers, sized to the defect.
When melanoma has spread to regional lymph nodes, treatment usually involves excision of the primary tumor plus further management of the affected nodes. Adjuvant therapy with immunotherapy (pembrolizumab or nivolumab) or targeted therapy is common for stage III disease. Your medical oncologist coordinates this part of the care.
Advanced melanoma has seen major treatment advances over the past decade. Immune checkpoint inhibitors (anti-PD-1 drugs such as pembrolizumab and nivolumab) have improved survival dramatically for many patients. BRAF and MEK inhibitors are used for tumors with specific mutations. Treatment is personalized based on molecular testing of the tumor.
Reconstruction of the Eyelid
Reconstruction starts after the melanoma is fully excised and margins are confirmed clear. This often means a staged approach: excision one day, reconstruction the next, and sometimes a temporary patch or ocular surface protection in between. The plan prioritizes clean margins over immediate cosmetic repair.
Options depend on defect size:
- Direct closure for small defects
- Tenzel semicircular flap for medium lower lid defects
- Tarsoconjunctival grafts from the opposite upper lid
- Hughes flap (two-stage) for large lower lid defects
- Cutler-Beard flap for large upper lid defects
- Full-thickness skin grafts, often from behind the ear
A well-planned reconstruction restores the ability to close the eye, protect the cornea, and drain tears. Cosmetic results improve over 6 to 12 months as scars mature and swelling resolves. Minor revisions are sometimes useful at 6 months or later to refine contour.
Immunotherapy and Systemic Treatment
Pembrolizumab and nivolumab are immune checkpoint inhibitors. They release brakes on the immune system, allowing it to attack melanoma cells. They are used in stage III and IV melanoma and have dramatically improved survival for many patients. Side effects include immune-related reactions in organs like the thyroid, skin, lungs, and gut, which oncologists monitor closely.
Combinations such as nivolumab plus ipilimumab may be used in select metastatic cases. These can give higher response rates than single agents but with more side effects. Treatment decisions balance benefits and risks based on disease burden, organ function, and patient preferences.
About half of cutaneous melanomas carry a BRAF mutation. BRAF and MEK inhibitors (such as dabrafenib and trametinib) attack these cells directly. Tumor molecular testing identifies patients who qualify. Responses are often rapid, though resistance can develop over time.
Prognosis and Survival
Melanoma in situ has an excellent prognosis when fully excised. 5-year overall survival is 88.6%, with disease-specific 5-year survival at 99.4%, per PMC/NIH 2022 data. Ongoing skin surveillance is important because patients with one melanoma are at higher risk of another.
Invasive disease has lower survival but is still often curable. 5-year overall survival for invasive eyelid melanoma is 77.1%, with disease-specific 5-year survival at 91.0%. Thin melanomas (Breslow under 1 millimeter) have near-normal survival. Thicker or ulcerated tumors have a higher risk of spread.
Stage IV melanoma was once almost uniformly fatal but is now treatable in many patients. 5-year survival for metastatic melanoma has risen from about 10% historically to over 50% in some subgroups with modern immunotherapy. Treatment continues to evolve rapidly.
Follow-Up Schedule
After treatment, follow-up is frequent. Schedules vary but commonly include:
- Eye doctor every 3 to 6 months for local exam and skin check
- Dermatology every 3 to 6 months for full-body skin check
- Imaging (ultrasound of nodes, CT, or PET-CT) as directed by the oncologist for higher-stage disease
Visits space out to every 6 to 12 months if there is no recurrence. Patients remain at risk of new primary melanomas for life and benefit from ongoing annual dermatology visits.
Between visits, check your skin monthly in good light. Feel for enlarged lymph nodes in front of the ear, along the jaw, under the chin, in the neck, and in the armpits and groin. Report new moles, changes to existing moles, or any lump you can feel to your care team.
Prevention
UV exposure is the largest modifiable risk factor. Daily facial sunscreen (SPF 30 or higher, mineral or chemical), UV-blocking wraparound sunglasses, a wide-brimmed hat, and avoidance of peak sun hours reduce UV damage. Reapply sunscreen every 2 hours outdoors and after swimming or sweating.
Tanning beds significantly increase melanoma risk. There is no safe tanning bed. Self-tanning products provide color without the cancer risk.
Once a year, take photographs of your face and body for comparison. New moles or changes in existing moles are easier to catch when you have a baseline to compare with. Dermatologists can perform full-body photography for high-risk patients.
People with many moles, atypical moles, a family history of melanoma, or prior melanoma should see a dermatologist with melanoma expertise regularly. Screening with dermoscopy, reflectance confocal microscopy, and full-body photography catches melanomas earlier.
Common Questions About Eyelid Melanoma
Yes, though intraocular melanoma (inside the eye) is a different disease from eyelid melanoma. Uveal melanoma, the most common primary eye cancer, arises from pigment cells inside the eyeball. It is evaluated and treated by ocular oncologists. Conjunctival melanoma is a separate, less common cancer on the surface of the eye. Each has its own treatment pathways.
Yes. Regular sunscreen use, especially from childhood and during peak sun hours, reduces the incidence of melanoma and other skin cancers. No sunscreen blocks 100% of UV, so it is used along with hats, sunglasses, and shade. Mineral sunscreens with zinc oxide or titanium dioxide are generally well tolerated around the eyes.
Adjuvant immunotherapy after surgery for stage III disease is typically given for about a year. Treatment for metastatic disease may continue longer, often until the cancer progresses, side effects become unacceptable, or a complete response is achieved. Your oncology team sets the plan based on response and tolerance.
A small excision and reconstruction often heals with a nearly invisible scar. Larger excisions need more complex reconstruction and may leave a visible change in the lid contour, a small patch of missing lashes, or a textural difference. Experienced oculoplastic surgeons plan reconstruction to minimize these changes, and revisions at 6 to 12 months can further refine the result.
Most melanomas are sporadic, but about 10% have a hereditary component. Mutations in genes like CDKN2A and BAP1 raise risk. If you have multiple family members with melanoma or other cancers, a consultation with a genetic counselor can help clarify your risk and guide screening.
First-degree relatives of someone with melanoma have a higher risk of melanoma themselves. Encourage your children to practice sun protection, know the ABCDE rule, and have annual skin exams with a dermatologist starting in young adulthood or earlier if they have multiple moles or other risk factors.
Get Evaluated for a Suspicious Eyelid Lesion
A pigmented or changing eyelid spot deserves prompt evaluation. An oculoplastic specialist can biopsy the lesion, coordinate pathology, and organize treatment with dermatology and oncology when needed. Early action makes the biggest difference in outcome. Schedule an evaluation today.